Key result
Finerenone is a nonsteroidal highly selective mineralocorticoid antagonist that decreases albuminuria and slows chronic kidney disease progression in patients with diabetes.
Why the study?
Despite renin angiotensin system blockers and SGLT2 inhibitors, the risk of renal disease progression in patients with diabetes and CKD remains unacceptably high.
Does finerenone improve renal and cardiovascular outcomes in patients with diabetes and chronic kidney disease?
Design
Review
Authors
Loading...
Finerenone may target inflammation and fibrosis in diabetic CKD; leaves open its additive benefit with current therapies in practice.
Does finerenone improve renal and cardiovascular outcomes in patients with diabetes and chronic kidney disease?
Finerenone provides added value in the management of diabetic kidney disease by reducing inflammation and fibrosis, thereby slowing CKD progression and offering cardiovascular protection.
Górriz et al. (2023) conducted a review in Diabetic kidney disease. Finerenone was evaluated. Finerenone is a nonsteroidal highly selective mineralocorticoid antagonist that decreases albuminuria and slows chronic kidney disease progression in patients with diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: